Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.47 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.47 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL236946 | 0.82 | EHMT2 (0.53) | HPGDSMN1; SMN2HSD17B10EHMT2EHMT1 | |
| SCHEMBL10403068 | 0.81 | EHMT2 (0.47) | HPGDSMN1; SMN2HSD17B10EHMT2EHMT1 | |
| SCHEMBL30495965 | 0.78 | EHMT2 (0.56) | HPGDSMN1; SMN2HSD17B10EHMT2EHMT1 | |
| SCHEMBL9888690 | 0.78 | EHMT2 (0.56) | HPGDSMN1; SMN2HSD17B10EHMT2EHMT1 | |
| SCHEMBL5061383 | 0.75 | EHMT2 (0.52) | HPGDSMN1; SMN2HSD17B10EHMT2EHMT1 | |
| SCHEMBL9967715 | 0.75 | EHMT2 (0.52) | HPGDSMN1; SMN2HSD17B10EHMT2EHMT1 | |
| SCHEMBL7818128 | 0.75 | EHMT2 (0.52) | HPGDSMN1; SMN2HSD17B10EHMT2EHMT1 | |
| SCHEMBL7459671 | 0.75 | EHMT2 (0.52) | HPGDSMN1; SMN2HSD17B10EHMT2EHMT1 | |
| SCHEMBL10403945 | 0.74 | SMN1; SMN2 (0.49) | HPGDSMN1; SMN2HSD17B10EHMT2EHMT1 | |
| Hydrochloric Acid SCHEMBL10706712 | 0.73 | EHMT2 (0.50) | HPGDSMN1; SMN2HSD17B10EHMT2EHMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10919941-B2 | Functional lipid constructs | KODE BIOTECH LIMITED (NZ) | 2021-02-16 | — | — | US | disclosed |
| US-10082515-B2 | Peptide-lipid constructs and their use in diagnostic and therapeutic applications | KODE BIOTECH LIMITED (NZ) | 2018-09-25 | — | — | US | disclosed |
| US-9802981-B2 | Functional lipid constructs | KODE BIOTECH LIMITED (NZ) | 2017-10-31 | — | — | US | disclosed |
| US-20170218027-A1 | FUNCTIONAL LIPID CONSTRUCTS | KODE BIOTECH LIMITED (NZ) | 2017-08-03 | — | — | US | disclosed |
| EP-2201025-B1 | FUNCTIONAL LIPID CONSTRUCTS | KODE BIOTECH LTD (NZ) | 2016-04-20 | — | — | EP | disclosed |
| EP-2198301-B1 | PEPTIDE-LIPID CONSTRUCTS AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | KODE BIOTECH LTD (NZ) | 2015-04-08 | — | — | EP | disclosed |
| US-20140350217-A1 | FUNCTIONAL LIPID CONSTRUCTS | KODE BIOTECH LIMITED (NZ) | 2014-11-27 | — | — | US | disclosed |
| US-8669084-B2 | Functional lipid constructs | KODE BIOTECH LIMITED (NZ) | 2014-03-11 | — | — | US | disclosed |
| US-20130280746-A1 | PEPTIDE-LIPID CONSTRUCTS AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | KODE BIOTECH LIMITED (NZ) | 2013-10-24 | — | — | US | disclosed |
| US-8394594-B2 | Peptide-lipid constructs and their use in diagnostic and therapeutic applications | KODE BIOTECH LIMITED (NZ) | 2013-03-12 | — | — | US | disclosed |
| US-7989446-B2 | 4-amino 5-cyanopyrimidine derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-08-02 | — | — | US | disclosed |
| US-20110171666-A1 | PEPTIDE-LIPID CONSTRUCTS AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | KODE BIOTECH LIMITED (NZ) | 2011-07-14 | — | — | US | disclosed |
| US-20110009620-A1 | 4-Amino-5-cyanopyrimidine derivatives | OTSUKA PHARMACEUTICAL CO., LTD. | 2011-01-13 | — | — | US | disclosed |
| US-7834002-B2 | 4-amino-5-cyanopyrimidine derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-11-16 | — | — | US | disclosed |
| US-20080182854-A1 | 4-Amino-5-Cyanopyrimidine Derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-07-31 | — | — | US | disclosed |
| EP-1740574-B1 | 4-AMINO-5-CYANOPYRIMIDINE DERIVATIVES | OTSUKA PHARMA CO LTD (JP) | 2007-06-27 | — | — | EP | disclosed |
| EP-1740574-A2 | 4-AMINO-5-CYANOPYRIMIDINE DERIVATIVES | Otsuka Pharmaceutical Company, Limited (JP) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005105778-A2 | 4-AMINO-5-CYANOPYRIMIDINE DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-11-10 | — | — | WO | disclosed |
| US-4914206-A | ANTIBIOTICS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1990-04-03 | — | — | US | disclosed |
| EP-0226896-A2 | Lankacidin derivatives and production thereof | Takeda Chemical Industries, Ltd. (JP) | 1987-07-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009620-A1 | 4-Amino-5-cyanopyrimidine derivatives | ADORA2A, ADORA1, ADORA3 | HPGD 781/4885SMN1; SMN2 4598/4885HSD17B10 3973/4885 |
| US-20080182854-A1 | 4-Amino-5-Cyanopyrimidine Derivatives | ADORA2A, ADORA1, ADORA3 | HPGD 781/4885SMN1; SMN2 4598/4885HSD17B10 3973/4885 |
| US-20170218027-A1 | FUNCTIONAL LIPID CONSTRUCTS | CETP, LCAT, LIPA | HPGD 1854/4885SMN1; SMN2 4732/4885HSD17B10 500/4885 |
| US-10919941-B2 | Functional lipid constructs | CETP, LCAT, LIPA | HPGD 1854/4885SMN1; SMN2 4732/4885HSD17B10 500/4885 |
| US-10082515-B2 | Peptide-lipid constructs and their use in diagnostic and therapeutic applications | PHOSPHO1, PTDSS2, PTDSS1 | HPGD 4114/4885SMN1; SMN2 2702/4885HSD17B10 3014/4885 |
| US-20140350217-A1 | FUNCTIONAL LIPID CONSTRUCTS | CETP, LCAT, SGMS1 | HPGD 2096/4885SMN1; SMN2 4558/4885HSD17B10 779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.